<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03628131</url>
  </required_header>
  <id_info>
    <org_study_id>2017-11-147</org_study_id>
    <nct_id>NCT03628131</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors</brief_title>
  <official_title>Safety and Efficacy of Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Republic of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of combination chemotherapy
      with Pazopanib in pediatric patients with relapsed/refractory solid tumor
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2018</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Pazopanib in combination chemotherapy</measure>
    <time_frame>42 days</time_frame>
    <description>Definition of dose-limiting toxicity (DLT)
Hematologic DLT: delayed recovery of ANC/platelets &gt; 42 days
Grade 3 creatinine elevation, proteinuria, hyperbilirubinemia, bleeding
Grade 2 arterial thrombosis
Any grade 4 toxicities except hematologic toxicities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of tumor response (neuroblastoma)</measure>
    <time_frame>4 weeks</time_frame>
    <description>as assessed by International Neuroblastoma Response
Primary tumor: CT and/or MRI; MIBG scan if available
Metastatic sites: bone marrow biopsies, CT/MRI, MIBG scan
CR (Complete response): No tumor (primary &amp; metastatic)
VGPR (Very good PR): Decreased by 90-99% (primary) &amp; no tumor (metastatic)
PR (Partial response): Decreased by &gt; 50% (primary &amp; metastatic)
MR (Mixed response): &gt; 50% reduction of any measurable lesion (primary or metastases) with &lt; 50% reduction in any other; &lt; 25% increase in any existing lesion
SD (Stable disease): No new lesions; &lt; 50% reduction but &lt; 25% increase in any existing lesion.
PD (Progressive disease): Any new lesion; increase of any measurable lesion by &gt; 25%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of tumor response (brain tumor)</measure>
    <time_frame>4 weeks</time_frame>
    <description>- as assessed by 2-dimensional measurement (the product of the tumor's longest diameter and its longest perpendicular diameter)
CR: complete disappearance of all previously measurable tumors.
PR: greater than 50% decrease in tumor size
SD: less than 50% reduction in tumor size or less than 25% increase in tumor size
PD: greater than 25% increase in tumor size or the appearance of a new tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of tumor response (other solid tumors)</measure>
    <time_frame>4 weeks</time_frame>
    <description>- as assessed by The Response Evaluation Criteria in Solid Tumors (RECIST version 1.1)
CR: Disappearance of all target lesions.
PR: At least a 30% decrease in the sum of diameters of target lesions
SD: Neither sufﬁcient shrinkage to qualify for PR nor sufﬁcient increase to qualify for PD
PD: At least a 20% increase in the sum of diameters of target lesions</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Relapsed Pediatric Solid Tumor</condition>
  <condition>Refractory Pediatric Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Pazopanib + conventional chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib</description>
    <arm_group_label>Pazopanib + conventional chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib</description>
    <arm_group_label>Pazopanib + conventional chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib</description>
    <arm_group_label>Pazopanib + conventional chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib</description>
    <arm_group_label>Pazopanib + conventional chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with refractory/relapsed solid tumor (Stable or progressive disease after
             1st-line treatment or relapse)

          -  Patients previously enrolled to &quot;Genomic diagnosis of pediatric tumors by NGS (IRB No.
             SMC 2015-11-053)&quot;

        Exclusion Criteria:

          -  Patients who had high-dose chemotherapy and autologous stem cell transplantation
             previously

          -  Patients with organ dysfunction as follows (creatinine elevation ≥ 1.5 x upper limit
             of normal (ULN), ejection fraction &lt;40%, significant arrhythmia or conduction
             disturbance)

          -  Patients who are not eligible to have scheduled treatment due to the other significant
             impaired organ function

          -  Patients with active bleeding

          -  Patients who are taking strong CYP3A4 inhibitors, QTc-prolonging drugs, antithrombotic
             agents, or anti-platelet agents

          -  Pregnant or nursing women

          -  Patients who can not swallow the pill
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ki Woong Sung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ki Woong Sung, MD, PhD</last_name>
    <phone>82-2-3410-3529</phone>
    <email>kiwoong.sung@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Ki Woong Sung</last_name>
      <phone>82-2-3410-3529</phone>
      <email>kwsped@skku.edu</email>
    </contact>
    <investigator>
      <last_name>Ki Woong Sung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>July 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>September 17, 2018</last_update_submitted>
  <last_update_submitted_qc>September 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

